210 related articles for article (PubMed ID: 34675258)
1. TCTP protein degradation by targeting mTORC1 and signaling through S6K, Akt, and Plk1 sensitizes lung cancer cells to DNA-damaging drugs.
Jeong M; Jeong MH; Kim JE; Cho S; Lee KJ; Park S; Sohn J; Park YG
Sci Rep; 2021 Oct; 11(1):20812. PubMed ID: 34675258
[TBL] [Abstract][Full Text] [Related]
2. Growth-factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the PI3-K/Akt/mTORC1 signalling pathway.
Bommer UA; Iadevaia V; Chen J; Knoch B; Engel M; Proud CG
Cell Signal; 2015 Aug; 27(8):1557-68. PubMed ID: 25936523
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
4. Identification of rictor as a novel substrate of Polo-like kinase 1.
Shao T; Liu X
Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
[TBL] [Abstract][Full Text] [Related]
5. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
[TBL] [Abstract][Full Text] [Related]
6. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy.
Ruf S; Heberle AM; Langelaar-Makkinje M; Gelino S; Wilkinson D; Gerbeth C; Schwarz JJ; Holzwarth B; Warscheid B; Meisinger C; van Vugt MA; Baumeister R; Hansen M; Thedieck K
Autophagy; 2017 Mar; 13(3):486-505. PubMed ID: 28102733
[TBL] [Abstract][Full Text] [Related]
7. Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase.
Copps KD; Hançer NJ; Qiu W; White MF
J Biol Chem; 2016 Apr; 291(16):8602-17. PubMed ID: 26846849
[TBL] [Abstract][Full Text] [Related]
8. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
10. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
[TBL] [Abstract][Full Text] [Related]
11. A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression.
Zhang F; Liu B; Wang Z; Yu XJ; Ni QX; Yang WT; Mukaida N; Li YY
Mol Cancer Res; 2013 Dec; 11(12):1508-20. PubMed ID: 24165482
[TBL] [Abstract][Full Text] [Related]
12. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
13. The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase.
Erazo T; Lorente M; López-Plana A; Muñoz-Guardiola P; Fernández-Nogueira P; García-Martínez JA; Bragado P; Fuster G; Salazar M; Espadaler J; Hernández-Losa J; Bayascas JR; Cortal M; Vidal L; Gascón P; Gómez-Ferreria M; Alfón J; Velasco G; Domènech C; Lizcano JM
Clin Cancer Res; 2016 May; 22(10):2508-19. PubMed ID: 26671995
[TBL] [Abstract][Full Text] [Related]
14. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Zhang B; Wang L; Zhang Q; Yan Y; Jiang H; Hu R; Zhou X; Liu X; Feng J; Lin N
Mol Oncol; 2019 Apr; 13(4):946-958. PubMed ID: 30663221
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
[TBL] [Abstract][Full Text] [Related]
17. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
[TBL] [Abstract][Full Text] [Related]
18. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.
Cao YY; Yu J; Liu TT; Yang KX; Yang LY; Chen Q; Shi F; Hao JJ; Cai Y; Wang MR; Lu WH; Zhang Y
Cell Death Dis; 2018 Jan; 9(2):17. PubMed ID: 29339720
[TBL] [Abstract][Full Text] [Related]
19. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
20. Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
Li J; Yan L; Luo J; Tong L; Gao Y; Feng W; Wang F; Cui W; Li S; Sun Z
Biomed Pharmacother; 2021 Jan; 133():110965. PubMed ID: 33166766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
